Literature DB >> 27068405

Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.

Maximilian Stahl1, Mina L Xu2, David P Steensma3, Raajit Rampal4, Melissa Much2, Amer M Zeidan2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27068405      PMCID： PMC7479634          DOI： 10.1007/s00277-016-2664-4

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  9 in total

Review 1.  Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Authors:  A Tefferi; J W Vardiman
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

Review 2.  Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice.

Authors:  Ayalew Tefferi; Michelle Elliott; Animesh Pardanani
Journal:  Curr Opin Hematol       Date:  2015-03       Impact factor: 3.284

3.  Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib.

Authors:  T L Lasho; A Mims; M A Elliott; C Finke; A Pardanani; A Tefferi
Journal:  Leukemia       Date:  2014-01-21       Impact factor: 11.528

4.  ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.

Authors:  Michelle A Elliott; Animesh Pardanani; Curtis A Hanson; Terra L Lasho; Christy M Finke; Alem A Belachew; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2015-07       Impact factor: 10.047

5.  CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.

Authors:  A Pardanani; T L Lasho; R R Laborde; M Elliott; C A Hanson; R A Knudson; R P Ketterling; J E Maxson; J W Tyner; A Tefferi
Journal:  Leukemia       Date:  2013-04-22       Impact factor: 11.528

Review 6.  The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.

Authors:  Jason Gotlib; Julia E Maxson; Tracy I George; Jeffrey W Tyner
Journal:  Blood       Date:  2013-07-29       Impact factor: 22.113

7.  Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Authors:  Julia E Maxson; Jason Gotlib; Daniel A Pollyea; Angela G Fleischman; Anupriya Agarwal; Christopher A Eide; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Cristina E Tognon; J Blake Pond; Robert H Collins; Basem Goueli; Stephen T Oh; Michael W Deininger; Bill H Chang; Marc M Loriaux; Brian J Druker; Jeffrey W Tyner
Journal:  N Engl J Med       Date:  2013-05-09       Impact factor: 91.245

8.  Somatic SETBP1 mutations in myeloid malignancies.

Authors:  Hideki Makishima; Kenichi Yoshida; Nhu Nguyen; Bartlomiej Przychodzen; Masashi Sanada; Yusuke Okuno; Kwok Peng Ng; Kristbjorn O Gudmundsson; Bandana A Vishwakarma; Andres Jerez; Ines Gomez-Segui; Mariko Takahashi; Yuichi Shiraishi; Yasunobu Nagata; Kathryn Guinta; Hiraku Mori; Mikkael A Sekeres; Kenichi Chiba; Hiroko Tanaka; Hideki Muramatsu; Hirotoshi Sakaguchi; Ronald L Paquette; Michael A McDevitt; Seiji Kojima; Yogen Saunthararajah; Satoru Miyano; Lee-Yung Shih; Yang Du; Seishi Ogawa; Jaroslaw P Maciejewski
Journal:  Nat Genet       Date:  2013-07-07       Impact factor: 38.330

9.  Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.

Authors:  Kim-Hien T Dao; Magdolna B Solti; Julia E Maxson; Elliott F Winton; Richard D Press; Brian J Druker; Jeffrey W Tyner
Journal:  Leuk Res Rep       Date:  2014-08-01
  9 in total
  15 in total

1.  Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib.

Authors:  Zohra Nooruddin; Nicholas Miltgen; Qi Wei; Jeffrey Schowinsky; Zengang Pan; Jennifer Tobin; Enkhtsetseg Purev; Jonathan A Gutman; William Robinson; Daniel A Pollyea
Journal:  Haematologica       Date:  2017-02-16       Impact factor: 9.941

Review 2.  JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Blood       Date:  2017-05-12       Impact factor: 22.113

3.  B-lymphoblastic leukemia arising in a patient with chronic neutrophilic leukemia.

Authors:  Craig S Boddy; Brent T Tan; Joseph Aoki
Journal:  Blood Adv       Date:  2020-11-10

4.  A t(1;9) translocation involving CSF3R as a novel mechanism in unclassifiable chronic myeloproliferative neoplasm.

Authors:  Jesús Gutiérrez-Abril; Iñigo Santamaría; Ana S Pitiot; Ana Gutiérrez-Fernández; Ángel Alvarez-Eguiluz; José M Vicente; Carmen Sanzo; Soledad González-Muñiz; Milagros Balbín; Xose S Puente
Journal:  Haematologica       Date:  2017-09-21       Impact factor: 9.941

Review 5.  Genomics of chronic neutrophilic leukemia.

Authors:  Julia E Maxson; Jeffrey W Tyner
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

Review 6.  Turning the tide in myelodysplastic/myeloproliferative neoplasms.

Authors:  Michael W N Deininger; Jeffrey W Tyner; Eric Solary
Journal:  Nat Rev Cancer       Date:  2017-06-23       Impact factor: 60.716

Review 7.  Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Authors:  Kim-Hien T Dao; Jeffrey W Tyner; Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

8.  Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis.

Authors:  S E Langabeer; K Haslam; J Kelly; J Quinn; R Morrell; E Conneally
Journal:  Clin Transl Oncol       Date:  2017-07-31       Impact factor: 3.405

9.  Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.

Authors:  Haijiao Zhang; Beth Wilmot; Daniel Bottomly; Kim-Hien T Dao; Emily Stevens; Christopher A Eide; Vishesh Khanna; Angela Rofelty; Samantha Savage; Anna Reister Schultz; Nicola Long; Libbey White; Amy Carlos; Rachel Henson; Chenwei Lin; Robert Searles; Robert H Collins; Daniel J DeAngelo; Michael W Deininger; Tamara Dunn; Than Hein; Marlise R Luskin; Bruno C Medeiros; Stephen T Oh; Daniel A Pollyea; David P Steensma; Richard M Stone; Brian J Druker; Shannon K McWeeney; Julia E Maxson; Jason R Gotlib; Jeffrey W Tyner
Journal:  Blood       Date:  2019-07-31       Impact factor: 25.476

Review 10.  Current Management of Chronic Neutrophilic Leukemia.

Authors:  Natasha Szuber; Ayalew Tefferi
Journal:  Curr Treat Options Oncol       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.